Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review.

Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related cardiotoxicity's definition, risk stratification, multimodality imaging, and use of cardiac biomarkers to detect clinical and/or subclinical myocardial dysfunction and electrical instability.

A comprehensive diagnostic approach to cardiac events in cancer patients receiving antineoplastic therapy: A systematic review.

Oncologic patients are vulnerable to a broad spectrum of cancer related cardiovascular complications during and/or after antineoplastic treatment. This article is dealing with the main drugs used in real world clinical practice, including conventional chemotherapy, targeted therapy, immunotherapy, radiotherapy and their potential cardiovascular toxicity. Diagnosis of cancer- related cardiovascular events requires thorough clinical evaluation, multimodality imaging techniques and cardiac biomarkers according to established guidelines of cardio-oncology.

Brugada-like ECG pattern due to giant mediastinal lipoma.

A case of a 33-year-old female who presented with mild dyspnea and palpitations is presented. Diagnostic investigation was consistent with a giant intrathoracic mass filling the right thoracic cavity and an abnormal electrocardiogram (Brugada-like pattern). The patient underwent surgical removal of the mass (benign lipoma) with a normal postoperative ECG pattern.